Christopher Southwood, MD
Neurocritical Care · Mobile, ALNPI 1215270616
Payments from drug & device makers
Across 124 payments — averaging $49.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$2K
- Stryker$1K
- Johnson & Johnson$630
- Imperative Care, Inc$541
- Scientia Vascular$164
- Microvention, Inc.$130
- plus $1K from 22 others
What the payments were for
- Travel & lodging$1,14118%
- Food & beverage$5,05582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 13 | $2,339 |
| Stryker | 35 | $1,315 |
| Johnson & Johnson | 22 | $630 |
| Imperative Care, Inc | 5 | $541 |
| Scientia Vascular | 1 | $164 |
| Microvention, Inc. | 2 | $130 |
| Lundbeck LLC | 5 | $116 |
| Philips North America LLC | 1 | $113 |
| Otsuka America Pharmaceutical, Inc. | 5 | $111 |
| AstraZeneca | 5 | $94 |
| Medtronic | 3 | $80 |
| Catalyst Pharmaceuticals, Inc. | 4 | $76 |
| AbbVie | 3 | $73 |
| CSL Behring | 2 | $52 |
| Chiesi USA, Inc. | 3 | $49 |
| Tanabe Pharma America, Inc. | 2 | $43 |
| Siemens Medical Solutions USA, Inc. | 1 | $35 |
| Amgen | 2 | $34 |
| Route 92 Medical, Inc. | 1 | $30 |
| Argenx US, Inc. | 1 | $27 |
| BD | 1 | $27 |
| Life Molecular Imaging Ltd | 1 | $22 |
| Trisalus Life Sciences, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Abbott | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Inspiremd Ltd | 1 | $15 |
| Terumo Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POD$3,423
- TARGET$594
- SURPASS EVOLVE$580
- TREVO$298
- NEUROFORM ATLAS$287
- ZOOM 88-T LARGE DISTAL PLATFORM$275
- Penumbra System$261
- Penumbra Coil 400$252
- TracStarLargeDistalPlatform$144
- Zoom88LargeDistalPlatform$144
- Zoom88_TLargeDitalPlatform$144
- ZoomReperfusionCatheter$144
- Benchmark$143
- Smart Coil$142
- Smart$137
- RED 72$117
- WEB Aneurysm Embolization System$113
- Azurion 7 B20$113
- ZOOM REPERFUSION CATHETER$108
How this compares
Too few neurocritical care providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $17,790 |
| Lacosamide | 13 | $1,814 |
| Levetiracetam | 33 | $1,588 |
| ClopidogrelClopidogrel Bisulfate | 51 | $438 |
| Atorvastatin Calcium | 30 | $344 |
| Rosuvastatin Calcium | 14 | $191 |
| Gabapentin | 12 | $113 |
Paid to pharmacies, not to this prescriber.
Other neurocritical care in Mobile
- John Andrew CoxMobile$6K
- Muhammad SaleemiMobile$2K
- Julio ChalelaMobile$16
- Viktor PerovicMontgomery$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.